Commentary on Pierce et al. (2016): Raising the bar of addiction treatment-first do no harm

Addiction

Volumn 111, Issue 2, 2016, Pages 309-310

  Banta Green, C J ^a   Coffin, P O ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Buprenorphine; Drug poisoning; Methadone; Mortality; Psychotherapy; Residential; Treatment

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC AGENT;

HUMAN; OPIOID-RELATED DISORDERS;

BUPRENORPHINE; HUMANS; METHADONE; NARCOTICS; OPIOID-RELATED DISORDERS;

EID: 84954237682     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13228     Document Type: Note

References (4)

1. Goldstein A., Herrera J. Heroin addicts and methadone treatment in Albuquerque: a 22-year follow-up. Drug Alcohol Depend 1995; 40: 139-50.
2. Walley A. Y., Doe-Simkins M., Quinn E., Pierce C., Xuan Z., Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 2013; 44: 241-7.
3. Zador D., Sunjic S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95: 77-84.
4. Kimber J., Larney S., Hickman M., Randall D., Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry 2015; 2: 901-8.